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A B S T R A C T
Objective: The objective of the study was to confirm the efficacy and safety of Astodrimer 1% Gel to
prevent recurrence of bacterial vaginosis.
Study design: 864 women with a diagnosis of bacterial vaginosis and a history of recurrent bacterial
vaginosis were enrolled in North America and first received oral metronidazole (500 mg twice daily for 7
days). Women successfully treated with metronidazole were randomly assigned 1:1 to Astodrimer 1% Gel
(N = 295) or placebo (N = 291) at a dose of 5 g vaginally every second day for 16 weeks, and followed for a
further 12 weeks off-treatment. The primary endpoint was recurrence of bacterial vaginosis (presence of
3 Amsel criteria) at or by Week 16. Secondary endpoints included time to recurrence, and recurrence of
subject-reported symptoms. Adverse events were monitored throughout the study.
Results: Astodrimer 1% Gel was superior to placebo for the primary and many secondary efficacy
measures. At or by Week 16, bacterial vaginosis recurred in 44.2 % (130/294) of women receiving
astodrimer and 54.3 % (158/291) receiving placebo (P = .015). Time to recurrence of bacterial vaginosis
was significantly longer for women receiving astodrimer compared with placebo (Kaplan-Meier survival
curves, P = .007). Recurrence of subject-reported symptoms at or by Week 16 was also significantly lower
in the astodrimer arm compared with placebo (vaginal odor and/or discharge, 27.9 % [75/269] vs 40.6 %
[108/266], P = .002). A significantly lower proportion of patients receiving astodrimer compared with
placebo had recurrence of bacterial vaginosis at or by Week 16 by other secondary measures, including
individual Amsel criteria (vaginal discharge and clue cells) and Nugent score 710. Recurrence of subject-
reported vaginal odor and/or discharge was significantly lower in the astodrimer arm compared with
placebo up to 8 weeks after cessation of therapy (36.1 % [97/269] vs 45.5 % [121/266], P = .027).
Adverse events were infrequent, and rates were generally similar between placebo and astodrimer
groups. Vulvovaginal candidiasis and urinary tract infection occurred more often in women receiving
astodrimer.
Conclusions: Astodrimer 1% Gel, administered every second day for 16 weeks, was effective and superior
to placebo for prevention of recurrent bacterial vaginosis in women with a history of recurrent BV, and
was well-tolerated.
© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Bacterial vaginosis (BV) is the most common vaginal infection
and twice as common as vulvovaginal candidiasis [1]. BV
recurrence rates are 43%–52% within 3–6 months of treatment
[2]. BV is a risk factor for serious sequelae, including pre-term
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birth, and acquisition and transmission of human immunodefi-
ciency virus (HIV) and other sexually transmitted infections (STIs)
[3,4]. Recurrent BV has significant psychosocial impacts on
women, including severely affecting self-esteem and sex life,
and carries a high economic burden [5,6].
There are no therapies with US regulatory approval for
prevention of recurrent BV, and there have been no other
adequately powered, well-controlled studies of interventions for
recurrent BV. Antibiotic therapies are used off-label over extended
periods for reducing recurrence of BV, but are associated with
increased risk of side effects [7] and potential for antibiotic
resistance development [8]. Long-term cure of BV is elusive given
the lifestyle factors associated with recurrence [9]. Therefore,
therapies suitable for longer-term use for preventing BV recur-
rence are urgently required [10,11].
Astodrimer sodium is a polyanionic dendrimer that blocks
attachment of bacteria to cells, preventing formation of bacterial
biofilms, which are central to the pathogenesis of BV and not
targeted by existing therapies [12–16]. Astodrimer Gel achieved
clinical cure in women with BV following a 7-day treatment course,
with 50–74 % cured 2–5 days after end of treatment, and was well-
tolerated and not systemically absorbed [17,18].
This phase 3 study assessed Astodrimer 1% Gel for preventing
recurrent BV.
2. Materials and methods
2.1. Study design
This was a phase 3, double-blind, multicenter, randomized,
placebo-controlled study assessing the efficacy and safety of
Astodrimer 1% Gel applied vaginally for 16 weeks compared with
placebo (hydroxyethyl cellulose placebo gel) to prevent BV
recurrence (Fig. 2).
The study complied with the Declaration of Helsinki, was
conducted in accordance with Good Clinical Practice, regulatory
guidelines, and relevant local legislation, and was approved by an
institutional review board on June 20, 2014 (Quorum Review, Inc.).
Patient enrolment commenced October 2014 with last follow-up in
February 2017.
Patients provided written informed consent and were screened
for eligibility at the Screening visit. Eligible patients with a current
symptomatic episode of BV and a history of recurrent BV were
enrolled in an open-label phase and received oral metronidazole
(500 mg), twice daily for 7 days. At the second visit (Baseline), 3–5
days after completion of metronidazole, women with resolution of
BV were randomized 1:1 to either Astodrimer 1% Gel or placebo
using a computer-generated randomization list based upon a
permutation block procedure.
The active gel and placebo were colorless, clear gels packaged in
identical vaginal applicators. Each applicator contained a single
dose (5 g) and was individually overwrapped in a sealed pouch.
Seventeen applicators (14 doses and 3 spare) were packed in a
tamper-evident carton labelled with a unique study medication/
patient identification number, allocated using an interactive
randomization system. One carton, enough for 4 weeks’ dosing,
was dispensed at Baseline, and at Week 4, 8 and 12 study visits.
Women self-administered a dose vaginally, every second day for 16
weeks (56 doses total) and attended visits for assessment of BV and
adverse events (AEs) every 4 weeks during, and for 12 weeks after
end of, treatment. Both care providers and patients were unaware
of treatment allocations. Women could withdraw from the study at
any time.
Women who had a BV recurrence prior to Week 16 stopped
treatment, ended the study and were offered BV therapy as per
local practice. A woman was considered to have completed the
study if she reached the final follow-up visit (Week 28) recurrence
free or had BV recurrence at any time.
2.2. Study population
Women aged 18–45 years with a current diagnosis of BV,
defined as presence of 3 Amsel criteria (discharge; vaginal fluid
pH  4.5; 20 % clue cells; and/or positive 10 % potassium
hydroxide whiff test) [19], Nugent score (NS) of 4–10 [20] and self-
report of characteristic BV symptoms (abnormal vaginal odor and/
or discharge), and a history of recurrent BV defined as 2
documented episodes of BV in the past year, were enrolled in the
open-label phase.
Women who were pregnant, planning to become pregnant,
lactating, or within 3 months of last pregnancy outcome, and
women testing positive for urinary tract infection (UTI), or who
had signs/symptoms of active genital herpes simplex virus or
tested positive for other STIs (Chlamydia trachomatis, Neisseria
gonorrhea or Trichomoniasis vaginalis) at Screening, were excluded.
Women who were asymptomatic and had clinical cure of BV
(i.e., negative Amsel criteria for discharge, whiff test and clue cells)
following the open-label phase, regardless of Nugent score, were
randomized for the double-blind treatment phase.
Concomitant systemic and vaginal antimicrobial therapies,
vaginal antifungals, or any other kind of vaginal products were not
permitted during the study.
2.3. Outcomes
The primary efficacy endpoint was recurrence of BV at or by
Week 16, defined as presence of 3 Amsel criteria (Fig. 2).
Secondary efficacy endpoints included recurrence of subject-
reported BV symptoms, individual Amsel criteria, NS 710, and 3
Amsel criteria and a NS  4, at or by Week 16. Time to BV
recurrence and BV recurrence at the follow-up visits after end of
the treatment period were also secondary efficacy endpoints.
AEs were monitored throughout the study.
2.4. Statistical analyses
Primary and secondary efficacy analyses using logistic regres-
sion, with missing BV recurrence data at Week 16 imputed as
recurrence, and treatment as the only factor in the model, were
performed on the modified intent-to-treat (mITT) population,
which comprised all women randomized who administered 1
dose of study product. This population was also used to assess
safety.
The primary efficacy endpoint was also analyzed for population
subgroups, including Nugent category at screening, method of
contraception, race, and sexual activity during the study.
Categorical variables were summarized using frequency counts
and percentages of patients in each category. Descriptive statistics
were calculated for each continuous variable.
Survival curves for time to recurrence were estimated using
Kaplan-Meier methodology. A log-rank test was used to test the
difference between survival curves of the treatment arms. Hazard
of BV recurrence was analyzed within the framework of the
Kaplan-Meier survival analysis.
Statistical analyses were performed using SAS (Version 9.2; SAS
Institute, Cary, NC).
2.5. Sample size calculation
Assuming BV recurrence rates of 32 % and 45 % for Astodrimer
Gel and placebo, respectively, a sample size of 308 evaluable
participants per treatment arm provided 90 % power with a 2-
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sided test to detect a treatment difference with alpha significance
level of 0.05. Therefore, approximately 310 per arm and 620
participants overall were to be randomized into the double-blind
treatment phase of the study.
3. Results
3.1. Disposition and demographics
A total of 864 women were enrolled in the open-label phase of
the study to receive metronidazole; 586/864 (67.8 %) eligible
women entered the double-blind treatment phase and were
randomized to either Astodrimer 1% Gel (N = 295) or placebo (N =
291) at 67 sites in the US, 4 in Canada, 4 in Mexico and 2 in Puerto
Rico. The mITT population included 585 women. Treatment groups
were well-balanced with respect to demographic and baseline
characteristics (Table 1). The majority of women completed the
study and were included in the mITT population (Fig. 1). In the
astodrimer group, 8.5 % of patients were lost to follow-up
compared with 10.3 % of patients in the placebo group. The
median compliance with the treatment regimen (administered
80%–120% of expected doses) was >96 % in both groups when
adjusted for missing doses due to menses.
3.2. Efficacy
Astodrimer 1% Gel was superior to placebo for the primary
endpoint, with 44.2 % (130/294) given astodrimer compared to
54.3 % (158/291) given placebo experiencing recurrence of BV at or
by Week 16; P = .015) (Table 2). The recurrence of subject-reported
symptoms of BV at or by Week 16 was also significantly lower in
the astodrimer arm compared with placebo (Table 2).
Kaplan-Meier survival curves for time to recurrence separated
after Week 4 and remained so at Week 16; P = .007 (Fig. 3).
Recurrence of all individual Amsel criteria at or by Week 16 was
lower in the astodrimer group than in the placebo group, with
exception of vaginal fluid pH (Table 2). In addition, a lower
proportion of patients receiving astodrimer compared with
placebo had BV recurrence at or by Week 16 based on NS 710,
and the composite of 3 Amsel criteria and NS  4 (Table 2).
During the 12-week follow-up phase, recurrence of BV (3 Amsel
criteria) in women given astodrimer was lower than in those given
placebo but differences were not statistically significant (Table 3).
Recurrence of BV symptoms of vaginal odor and/or discharge
was statistically significantly lower in the astodrimer arm
compared with placebo up to 8 weeks after cessation of therapy
(Table 3).
Subgroup recurrence rates were in line with those for the mITT.
The Breslow-Day test for homogeneity of odds ratios of astodrimer
versus placebo was non-significant for each subgroup factor (P >
.150, except Age, P = .098); data not shown. Lower recurrence at or
by Week 16 for women randomized to astodrimer compared to
placebo was statistically significant for several subgroup catego-
ries, including women with screening NS 710 (46.2 % [108/234] vs
57.7 % [128/222], P = .014), black women (53.7 % [79/147] vs 68.1 %
[96/141], P = .013), women who had penile-vaginal sexual acts
during the treatment period (38.9 % [96/247] vs 50.6 % [121/239], P
= .009), and women who used condoms during treatment (33.0 %
[29/88] vs 49.4 % [44/89], P = .027).
3.3. Safety/tolerability
The overall incidence of AEs was 54.1 % (159/294) for
Astodrimer Gel and 47.4 % (138/291) for placebo (Table 4). AEs
potentially treatment-related occurred in 12.6 % (37/294) of
astodrimer patients and 11.3 % (33/291) for placebo.
Most AEs were mild or moderate in intensity, and self-limiting.
During treatment, 1.7 % (5) women in each group reported severe
AEs; none were considered treatment related. In the astodrimer
group, 1 participant discontinued treatment due to menorrhagia
and 1 participant due to vulvovaginal candidiasis, which was
considered possibly related to treatment. For placebo, 1 participant
discontinued due to each of vulvovaginal candidiasis, type 2
diabetes mellitus, headache and abdominal pain, and 1 participant
discontinued after experiencing vaginal inflammation, vulvovagi-
nal burning sensation, vulvovaginal pruritus and BV considered
possibly treatment-related.
Serious AEs were reported for 3/294 (1.0 %) women in the
astodrimer group and 3/291 (1.0 %) in placebo, and none was
considered to be potentially treatment related.
Table 1
Screening Characteristics (mITT population), by Treatment Group.
Astodrimer Gel (N = 294) Placebo (N = 291)
Age (yr)
Mean [SD] 31.6 [7.23] 31.6 [6.99]
Range 18 to 45 18 to 45
Race, n (%)
Black 147 (50.0) 141 (48.5)
White 115 (39.1) 113 (38.8)
All Othersa 32 (10.9) 37 (12.7)
Ethnicity, n (%)
Not Hispanic or Latino 209 (71.1) 206 (70.8)
Hispanic or Latino 85 (28.9) 85 (29.2)
Screening Nugent score, n (%)
0–3 3 (1.0) 1 (0.3)
4–6 57 (19.4) 67 (23.0)
7–10 234 (79.6) 222 (76.3)
Missing 0 1 (0.3)
Number of BV episodes in 12 months prior to enrolmentb
1 2 (0.7) 0
2 187 (63.6) 198 (68.0)
3–4 94 (32.0) 82 (28.2)
5 11 (3.7) 11 (3.8)
BV = bacterial vaginosis; SD = standard deviation.
a All Others = American Indian or Alaskan Native, Asian, Native Hawaiian or Other Pacific Islander, Other.
b Not including a current episode.
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Vulvovaginal candidiasis was reported in 18.0 % (53/294) and
13.7 % (40/291) women in the astodrimer and placebo groups,
respectively, during treatment and 20.1 % [59/294] vs 17.2 % [50/
291] for the overall study period. Vulvovaginal candidiasis
considered potentially treatment-related was reported in 6.8 %
(20/294) and 4.8 % (14/291) of women using astodrimer or placebo,
respectively, during treatment. During follow-up, vulvovaginal
candidiasis rates were 4.1 % (12/294) for astodrimer and 5.8 % (17/
Fig. 1. CONSORT diagram.
Fig. 2. Study design flowchart.
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291) for placebo. During treatment, UTI rates were 7.8 % (23/294)
for astodrimer and 2.4 % (7/291) for placebo.
4. Discussion
Astodrimer 1% Gel, administered every second day for 16
weeks, was effective and superior to placebo for the prevention of
BV recurrence in women with a history of recurrent BV. The
primary efficacy finding was supported by multiple secondary
endpoints, including significantly longer time to recurrence and
lower recurrence of symptoms, which was significant up to 8
weeks after end of treatment.
Astodrimer 1% Gel was well-tolerated, with the incidence of AEs
generally similar between the astodrimer and placebo arms. Rates
of candidiasis were generally low. The majority of patients
completed the study
Table 2
Efficacy Outcomes at or by Week 16 (mITT population), by Treatment Group.
BV Recurrence Endpoint Astodrimer Placebo RR (95 % CIb) P valueb
n/N (%) [95 % CIa] n/N (%) [95 % CIa]
Primary Endpoint
3 Amsel criteria 130/294 (44.2) [38.5, 50.1] 158/291 (54.3) [48.4, 60.1] 0.81 (0.69, 0.96) 0.015
Subject-reported BV Symptoms
Vaginal Discharge 56/275 (20.4) [15.8, 25.6] 79/276 (28.6) [23.4, 34.3] 0.71 (0.53, 0.96) 0.025
Vaginal Odor 57/275 (20.7) [16.1, 26.0] 87/276 (31.5) [26.1, 37.4] 0.66 (0.49, 0.88) 0.004
Vaginal Discharge and/or Odor 75/269 (27.9) [22.6, 33.6] 108/266 (40.6) [34.6, 46.8] 0.69 (0.54, 0.87) 0.002
Individual Amsel Criteria
Vaginal Discharge 97/276 (35.1) [29.5, 41.1] 125/276 (45.3) [39.3, 51.4] 0.78 (0.63, 0.95) 0.015
Positive Whiff Test 99/276 (35.9) [30.2, 41.8] 119/276 (43.1) [37.2, 49.2] 0.83 (0.68, 1.02) 0.082
Clue Cells 20 % 104/274 (38.0) [32.2, 44.0] 132/273 (48.4) [42.3, 54.5] 0.79 (0.65, 0.95) 0.014
pH >4.5 175/276 (63.4) [57.4, 69.1] 175/276 (63.4) [57.4, 69.1] 1.00 (0.88, 1.14) 1.000
Composite Definition 81/276 (29.3) [24.0, 35.1] 111/276 (40.2) [34.4, 46.3] 0.73 (0.58, 0.92) 0.008
Nugent Score 710 95/240 (38.5) [32.4, 44.8] 135/273 (49.5) [43.4, 55.5] 0.78 (0.64, 0.95) 0.012
BV = bacterial vaginosis; CI = confidence interval; RR = relative risk.
a Clopper Pearson CI.
b Wald CI and P value.
Fig. 3. Kaplan-Meier survival curves for time to recurrence of bacterial vaginosis at or by Week 16 (modified intent-to-treat population).
a Log-rank test for the difference between the survival curves of the two treatment groups.
Table 3
Efficacy Outcomes During Follow-up (mITT population), by Treatment Group.
Endpoint Astodrimer Placebo RR (95 % CIb) P valueb
n/N (%) [95 % CIa] n/N (%) [95 % CIa]
BV Recurrence (3 Amsel criteria)
Week 20 191/294 (65.0) [59.2, 70.4] 203/291 (69.8) [64.1, 75.0] 0.93 (0.83, 1.04) 0.217
Week 24 194/294 (66.0) [60.3, 71.4] 213/291 (73.2) [67.7, 78.2] 0.90 (0.81, 1.00) 0.059
Week 28 197/294 (67.0) [61.3, 72.4] 206/291 (70.8) [65.2, 76.0] 0.95 (0.85, 1.06) 0.323
Subject-reported BV Symptoms – Vaginal Discharge and/or Odor
Week 20 87/269 (32.3) [26.8, 38.3] 110/266 (41.4) [35.4, 47.5] 0.78 (0.62, 0.98) 0.031
Week 24 97/269 (36.1) [30.3, 42.1] 121/266 (45.5) [39.4, 51.7] 0.79 (0.64, 0.97) 0.027
Week 28 107/269 (39.8) [33.9, 45.9] 124/266 (46.6) [40.5, 52.8] 0.85 (0.70, 1.04) 0.111
BV = bacterial vaginosis; CI = confidence interval; RR = relative risk.
a Clopper Pearson CI.
b Wald CI and P value.
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The current study of Astodrimer 1% Gel represents the largest
and first adequately powered, randomized, placebo-controlled
study of a therapy for preventing recurrent BV.
Some approved antibiotics or investigational therapies have
been shown to reduce recurrence of BV in limited clinical studies
that have been generally non-randomized, not placebo-controlled,
and/or not adequately powered [7,21–23]. Nevertheless, off-label
regimens of products not approved for prevention, including
topical metronidazole and topical boric acid over periods of 4–6
months, together with fluconazole to prevent likely secondary
candidiasis, are recommended in treatment guidelines for reduc-
ing recurrent BV [24].
The proportion of women with known BV recurrence (i.e.,
missing data not imputed) for Astodrimer 1% Gel (34.9 % [88/252]
vs 46.6 % [116/249] for placebo) was comparable with that seen in a
similarly designed study of topically applied metronidazole gel
given for 16 weeks (25.5 %) [7].
The difference in recurrence rates between astodrimer and
placebo narrowed progressively after end of treatment, but women
in the astodrimer group recurred later than placebo, and therefore
had more recurrence free days. In addition, recurrence of
symptoms of BV was statistically significantly lower for astodrimer
compared with placebo up to Week 24, 8 weeks after end of
therapy, indicating a clinically meaningful residual benefit.
Treatment with astodrimer helped maintain normal vaginal
flora, with lower BV recurrence rates as determined by Nugent
score and the combination of Amsel criteria and Nugent score.
The proportion of women with vulvovaginal candidiasis
receiving astodrimer (18 % during treatment, 20.1 % overall) was
similar to placebo and less than half that reported during a study of
16 weeks’ treatment with topical metronidazole 0.75 % gel (43.1 %
vs 20.5 % in placebo) [7].
The slightly higher proportion of women with UTI for
astodrimer compared with placebo could be potentially explained
by the longer symptom-free period associated with use of
astodrimer allowing a resumption of a more normal frequency
of intercourse, consistent with slightly higher sexual functioning
scores observed in this study. In any case, the incidence of
uncomplicated UTI in young, sexually active women in the US is
reported to be approximately 0.5 episodes per person per year [25].
The incidence in women using astodrimer in this study was 0.37
episodes per person per year.
There were no other notable differences in AEs reported for
astodrimer and placebo.
Astodrimer is a novel dendrimer administered vaginally and is
not systemically absorbed. Data show that it inhibits formation of
and disrupts biofilms due to its ability to block bacterial adhesion.
Given this profile, astodrimer avoids issues typically associated
with conventional antibiotics, such as systemic side effects and
antibiotic resistance, and is suitable as an effective and safe
alternative for the long-term management of recurrent BV,
addressing an unmet medical need.
Subgroup analyses showed statistically significant differences
in clinical response between astodrimer and placebo in population
groups with recognized risk factors for BV, such as black women,
those engaging in penile-vaginal sexual acts during the treatment
period, and a high screening NS of 710, suggesting benefit of
preventive treatment with astodrimer in these high-risk groups.
Subgroup analyses were exploratory in nature and results should
be interpreted with caution.
The findings of this Phase 3 study support the clinical utility of
Astodrimer 1% Gel as a novel treatment for prevention of BV
recurrence in women suffering from recurrent BV. The product has
regulatory approval in Europe, Australia and a number of countries
in Asia, and additional safety information will be derived from
routine post-market surveillance activities.
The study is the largest randomized, double-blind, placebo-
controlled study of a therapy to prevent recurrent BV and was
adequately powered to detect a difference in rates of BV recurrence
between astodrimer- and placebo-treated women.
The results of reduced recurrence of BV at Week 16 are
consistent with the ability of Astodrimer 1% Gel to achieve clinical
cure of BV at the end of a 7-day treatment period, as demonstrated
in phase 2 and 3 clinical studies [17,18].
5. Conclusions
The study supports a role for Astodrimer 1% Gel as an effective
long-term therapy to prevent recurrence of BV, with a novel
mechanism of action related to blocking of biofilms. The product is
not systemically absorbed, and offers patients and clinicians a
unique treatment option that avoids potential issues associated
with existing antibiotics.
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